At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 74 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 250
- Started
- 2020-10-20
- Last checked
- 2026-05
Plain English Summary
What is this study?
- • Testing a new treatment for cancer
- • Clinical study - 250 participants
- • The MR BIO study aims to understand the changes in the tumour and normal tissues during a course of radiotherapy
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with cancer
Where?
- • Manchester - The Christie NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The MR BIO study aims to understand the changes in the tumour and normal tissues during a course of radiotherapy. This is accomplished by studying the MR images taken during each treatment session on the MR Linear accelerator (MR Linac). The overarching hypothesis is that changes in MR imaging and biological parameters from blood, tissue, or urine biomarkers can be measured during radiotherapy and associated with clinical outcome. The MR Linac is a new radiotherapy machine with an on board MR scanner. This enables us to take images with high resolution and target the tumours more precisely and also reduce the dose to normal tissues. All patients undergoing treatment in the MR Linac at the Christie hospital will be considered for enrolment regardless of tumour site being treated. The study participants will receive the standard of care treatment for their disease condition. In addition, they will be requested to give weekly blood and urine samples during the course of radiotherapy and at first follow up. On completion of radiotherapy treatment, the participants will continue to be on standard of care follow up protocol with the treating oncologist. A small cohort of ten healthy volunteers will also be recruited to the study to develop and select some of the MR sequences only; they will not provide blood or urine samples. The healthy volunteers will be scanned for no more than one hour per session for a maximum of two sessions in total. These optimised sequences can then be used in the patient cohort.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Treatment history
Treatments you must have had:
- ✓ through the treatment period
- ✓ no known or suspected significant medical condition
What the study is looking for
- ✓Patient volunteers must be able to give blood and/or urine sample as required through the treatment period.
- ✓Non-patient (healthy) volunteers must have no known or suspected significant medical condition.
Who cannot take part
- ✗The following apply to both patients and healthy volunteers:
- ✗Any conditions that would be a contra-indication to MRI including:
- ✗Failure to satisfy MRI Safety Screening Form
- ✗Implanted pacemakers and/or pacing wires
- ✗Cochlear implants
See the full criteria
Where Is This Study? (1 UK site)
The Christie NHS Foundation Trust
Manchester M20 4BX, United Kingdom
How to Get in Touch
Rachel Reed, MSc
Sponsor contactCONTACT
Kimberley Reeves, PhD
Sponsor contactCONTACT